COST-EFFECTIVENESS OF ANTENATAL ANTI-D PROPHYLAXIS

This paper estimates the incremental cost-effectiveness of providing a ntenatal anti-D prophylaxis in varying dose sizes to either primigravi dae or all Rh D negative women. It presents a model for calculating th e net cost per 1000 'at risk' women based on the costs of anti-D proph ylaxis and the future NHS costs avoided. Incremental cost-effectivenes s is measured in terms of the net cost per Rh D-alloimmunization and t he net cost per Rh HD loss prevented. Programmes for Rh D negative pri migravidae are more cost-effective than the same dose protocol extende d to all Rh D negative women. The 1 x 1250 in programme is the most co st-effective option.